The Armchair Analyst
Login
Subscribe
The Armchair Analyst
Level up your knowledge on ASX life sciences companies.
Dec 12, 2025
$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?
Jason Segal
Dec 11, 2025
Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer
Jason Segal
Dec 09, 2025
Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t
Jason Segal
Dec 08, 2025
Immutep drops a US$370M deal... at 6:54pm
Jason Segal
Dec 07, 2025
A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts
Jason Segal
Dec 05, 2025
Are AI-Predicted Clinical Trials the Future of Drug Development?
Jason Segal
Dec 03, 2025
The Moment Invion (IVX) Became “Investible” for me
Jason Segal
Dec 03, 2025
The Hidden Signals Found in AGM Updates
Jason Segal
Dec 02, 2025
Inside the Visionflex Lazarus Story
Jason Segal
Dec 01, 2025
What happens when a biotech stock goes up on "no news"...
Jason Segal
Nov 28, 2025
Biotech green shoots emerge in Australia and the US
Jason Segal
Nov 27, 2025
What does a "leveraged" clinical trial bet look like
Jason Segal
First
Back
1
2
Next
Last
